Financial Performance - The company's operating revenue for Q1 2021 was ¥206,120,330.21, representing a 398.23% increase compared to ¥41,370,743.10 in the same period last year[7] - Net profit attributable to shareholders was ¥2,636,189.61, a 162.93% increase from a loss of ¥4,189,298.20 in the previous year[7] - The net profit after deducting non-recurring gains and losses was ¥206,069.19, improving by 103.38% from a loss of ¥6,104,842.12[7] - The basic earnings per share rose to ¥0.0066, a 162.69% improvement from a loss of ¥0.0105 per share in the same period last year[7] - Operating revenue surged by 398.23% to ¥206,120,330.21, with a year-on-year growth of 24% attributed to enhanced channel development and increased product sales.[15] - Operating profit for the quarter was CNY 5,488,722.17, compared to CNY 1,151,407.84 in the same period last year[41] - Net profit for the quarter reached CNY 5,664,525.34, a significant recovery from a net loss of CNY 201,504.74 in the previous year[41] - The company reported a total comprehensive income of CNY 5,664,525.34, compared to a loss of CNY 201,504.74 in the same period last year[42] Assets and Liabilities - The company's total assets increased by 18.05% to ¥993,722,701.01 from ¥841,755,807.01 at the end of the previous year[7] - Current liabilities surged to CNY 235,388,619.99, up from CNY 100,283,777.44, representing an increase of about 134%[29] - The company's total liabilities reached CNY 274,420,476.31, up from CNY 137,049,500.13, indicating a growth of approximately 100%[29] - The total owner's equity rose to CNY 719,302,224.70 from CNY 704,706,306.88, reflecting an increase of about 2%[30] - The company reported a total of CNY 361,819,950.99 in current assets, including cash and cash equivalents of CNY 53,209,609.39[54] - Non-current assets were valued at CNY 405,910,422.30, with fixed assets contributing CNY 189,297,529.32[55] Cash Flow - The net cash flow from operating activities was -¥31,810,151.06, a decline of 209.32% compared to -¥10,274,152.98 in the same period last year[7] - The net cash flow from investing activities improved by 124.69% to ¥25,753,463.47, due to changes in the purchase of financial products.[16] - Cash inflow from operating activities totaled CNY 151,681,265.25, significantly up from CNY 49,709,367.63 in the previous period[44] - Cash outflow from operating activities amounted to CNY 183,491,416.31, compared to CNY 59,983,520.61 in the prior period, resulting in a net cash flow from operating activities of -CNY 31,810,151.06[45] - The net cash flow from investment activities was CNY 25,753,463.47, a recovery from -CNY 104,301,239.14 in the previous period[46] - The ending balance of cash and cash equivalents stood at CNY 131,569,109.02, compared to CNY 90,903,378.34 in the prior period[46] Shareholder Information - The top shareholder, Kunming Qunxing Investment Co., Ltd., holds 41.38% of the shares, totaling 165,723,830 shares[11] - There were no repurchase transactions conducted by the top 10 shareholders during the reporting period[12] Inventory and Receivables - Accounts receivable increased by 183.84% to ¥124,661,545.64 due to increased sales by the subsidiary Yunnan Longjin Pharmaceutical Co., Ltd.[15] - Inventory rose by 119.68% to ¥120,101,099.81 as a result of increased stock by the subsidiary Yunnan Longjin Pharmaceutical Co., Ltd.[15] Expenses - Operating costs skyrocketed by 2404.95% to ¥150,973,564.57, primarily due to increased costs from the subsidiary Yunnan Longjin Pharmaceutical Co., Ltd.[15] - Sales expenses increased by 34.53% to ¥40,125,797.76, driven by higher marketing and promotion costs alongside increased revenue.[15] - Research and development expenses amounted to CNY 2,173,595.90, an increase from CNY 1,626,097.75 in the previous period[40] Other Financial Metrics - The weighted average return on net assets was 0.41%, up from -0.67% in the previous year[7] - The company reported a credit impairment loss increase of 589.37% to -¥2,536,290.46, linked to a rise in accounts receivable.[16] - The company incurred a tax expense of CNY -179,349.76, compared to a tax expense of CNY 320,977.03 in the previous year[41] Audit and Compliance - The company has not undergone an audit for the Q1 2021 report, which may affect the reliability of the financial data presented[56] - The adjustment for the new leasing standards was not applicable for the company in the current reporting period[56]
龙津药业(002750) - 2021 Q1 - 季度财报